Holen Sie sich die Stockscreener-App
91.84
0.21%
0.19
Vorhandelsmarkt:
92.14
0.30
+0.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Merit Financial Group LLC Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Can Gilead Sciences Sustain Its Growth Momentum In 2025? - Barchart
Can Gilead Sciences Sustain Its Growth Momentum in 2025? - Yahoo Finance
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Gilead Sciences Q2 EPS Estimate Boosted by Zacks Research - MarketBeat
Liberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Nexus Investment Management ULC Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Premier Path Wealth Partners LLC Has $744,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Arkadios Wealth Advisors Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Boston Common Asset Management LLC Sells 53,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wedge Capital Management L L P NC Sells 86,409 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Park Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Avanza Fonder AB Takes $11.74 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock - MarketBeat
Advanced biologic developer Gilead cites manufacturing efficiencies as CAR-T advantage in 2025 - BioProcess Insider
Gilead Sciences CFO sells shares worth $228,375 - MSN
Earnings Preview: What to Expect From Gilead Sciences’ Report - Nasdaq
Earnings Preview: What To Expect From Gilead Sciences’ Report - Barchart
Occidental Asset Management LLC Acquires 3,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLC - MarketBeat
Gateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus.com
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others - Yahoo Finance
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy - FiercePharma
Gilead, US Settle Billion-Dollar Patent Feud Over HIV Drugs (1) - Bloomberg Law
Gilead's Kite taps longtime Amgen alum as new global commercial head - FiercePharma
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
JPM Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Rovin Capital UT ADV Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
USA Financial Formulas Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Primary Sclerosing Cholangitis Market Deep Research Report Forecast by 2031 | Acorda Therapeutics, Inc., - EIN News
Gilead And US Settle HIV Drug Patent Dispute - Finimize
Assenagon Asset Management S.A. Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal - Law360
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead reportedly settles CDC patent dispute over HIV drugs - Seeking Alpha
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills - STAT
Gilead Sciences, US government settle patent case over HIV prevention drugs - MSN
Autologous Cell Therapy Market Set to Witness Significant Growth by 2025-2032: Bristol Myers Squibb, Gilead - EIN News
40 Under 40: Rasika Iyer, Gilead Sciences - MM+M Online
April 17th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Global Financial Private Client LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wright Investors Service Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies - GuruFocus.com
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
Latham & Watkins Advises LEO Pharma in Strategic Partnership With Gilead Sciences - Latham & Watkins LLP
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Capital Investment Advisors LLC - MarketBeat
Gilead and Leo Pact Adds Fuel To Hot STAT6 Inflammation Space - Citeline News & Insights
Gilead and LEO Pharma link on programmes for inflammatory conditions - Yahoo Finance
TT International Asset Management LTD Cuts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program - Contract Pharma
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO - BioSpace
Czech National Bank Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
0.00%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):